A U.S. Food and Drug Administration advisory panel voted Thursday to endorse Moderna’s coronavirus vaccine, clearing the way for FDA leaders to authorize emergency mass distribution amid an ongoing surge of COVID-19 cases across the country.
The vote was 20-0. One committee member abstained.
The committee was charged with voting on the following question: “Based on the totality of scientific evidence available, do the benefits of the Moderna COVID-19 Vaccine outweigh its risk for use in individuals 18 years of age and older?”
The highly anticipated meeting included members of the FDA’s Center for Biologics Evaluation and Research advisory committee, outside vaccine experts and Moderna representatives.
CORONAVIRUS IN THE US: STATE-BY-STATE BREAKDOWN
Although significant, the committee’s vote in favor of emergency use authorization (EUA) is not final. The vote will now go before FDA officials who will decide whether to grant EUA based on the committee’s findings. Such approval would come about a week after the regulatory agency granted EUA to Pfizer’s COVID-19 vaccine for individuals aged 16 and older, which states have begun rolling out to health care workers this week.
A similar process ensued after a panel of independent experts advising the Centers for Disease Control and Prevention (CDC) recently voted that health care workers and residents of long-term care facilities will be the first to receive the long-awaited coronavirus vaccine. That decision required approval from CDC Director Dr. Robert Redfield.
The FDA panel’s vote to approve the company’s EUA was expected, with documents posted ahead of the agency’s scheduled Dec. 17 meeting showing that the candidate met the FDA’s requirements for emergency use.
HOW DO THE MODERNA AND PFIZER CORONAVIRUS VACCINES COMPARE?
An FDA committee’s review of Moderna’s coronavirus vaccine emergency use authorization application found “no specific safety concerns” in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection, potentially paving the way for a second COVID-19 jab to enter the scene.
The panel also found that the vaccine reduced the risk of confirmed COVID-19 – including severe cases – occurring at least 14 days after the second dose.
ALLERGIC REACTIONS TO VACCINES ARE RARE, SHORT-LIVED
The committee was careful to note that there wasn’t enough data to evaluate the duration of protection in relation to the vaccine, effectiveness in certain high-risk populations such as immunocompromised individuals, effectiveness in individuals who have previously been infected with SARS-CoV-2, or effectiveness in pediatric populations. There also wasn’t enough data for the committee to evaluate future vaccine effectiveness in relation to changes in the virus, effectiveness against asymptomatic infection, and effectiveness against long-term effects of COVID-19, effectiveness against mortality, or effectiveness against transmission of SARS-CoV-2.
DO YOU NEED A COVID-19 VACCINE IF YOU’VE ALREADY HAD THE VIRUS?
Not unlike Pfizer and BioNTech’s vaccine, the Moderna jab did elicit non-serious adverse reactions such as pain at the injection site, fatigue, headache, muscle pain, joint pain and chills. The reactions were characterized as generally mild to moderate.
The FDA did consider three serious adverse reactions, including nausea and vomiting, and facial swelling. An incident of Bell’s palsy also occurred in a vaccine recipient, “for which a causal relationship to vaccination cannot be concluded at this time.”
CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE
From an accessibility standpoint, the Moderna vaccine, which proved more than 90% effective in late-stage clinical trials and requires two doses given weeks apart, does not require ultra-cold storage requirements, and comes in smaller batches, compared to the 975 doses with the Pfizer-BioNTech vaccine.
Upon formal FDA approval, which would mark the first such approval for Moderna, Americans could see an initial 6 million doses distributed next week.
Fox News’ Alexandria Hein and Kayla Rivas contributed to this report.